keyword
MENU ▼
Read by QxMD icon Read
search

effect of angiotensin 2 on the kidneys

keyword
https://www.readbyqxmd.com/read/29767459/long-term-effects-of-patiromer-for-hyperkalaemia-treatment-in-patients-with-mild-heart-failure-and-diabetic-nephropathy-on-angiotensin-converting-enzymes-angiotensin-receptor-blockers-results-from-amethyst-dn
#1
Bertram Pitt, George L Bakris, Matthew R Weir, Mason W Freeman, Mitja Lainscak, Martha R Mayo, Dahlia Garza, Rezi Zawadzki, Lance Berman, David A Bushinsky
AIMS: Chronic kidney disease (CKD) in heart failure (HF) increases the risk of hyperkalaemia (HK), limiting angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB) use. Patiromer is a sodium-free, non-absorbed potassium binder approved for HK treatment. We retrospectively evaluated patiromer's long-term safety and efficacy in HF patients from AMETHYST-DN. METHODS AND RESULTS: Patients with Type 2 diabetes, CKD, and HK [baseline serum potassium >5...
May 16, 2018: ESC Heart Failure
https://www.readbyqxmd.com/read/29747407/transcription-factors-as-therapeutic-targets-in-chronic-kidney-disease
#2
REVIEW
Akihito Hishikawa, Kaori Hayashi, Hiroshi Itoh
The growing number of patients with chronic kidney disease (CKD) is recognized as an emerging problem worldwide. Recent studies have indicated that deregulation of transcription factors is associated with the onset or progression of kidney disease. Several clinical trials indicated that regression of CKD may be feasible via activation of the transcription factor nuclear factor erythroid-2 related factor 2 (Nrf2), which suggests that transcription factors may be potential drug targets for CKD. Agents stabilizing hypoxia-inducible factor (HIF), which may be beneficial for renal anemia and renal protection, are also now under clinical trial...
May 9, 2018: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/29739827/hyperfiltration-in-ubiquitin-c-terminal-hydrolase-l1-deleted-mice
#3
Naomi C Boisvert, Chet E Holterman, Jean-François Thibodeau, Rania Nasrallah, Eldjonai Kamto, Cesar H Comin, Luciano da F Costa, Anthony Carter, Richard L Hébert, Alexey Gutsol, Gregory O Cron, Baptiste Lacoste, Douglas A Gray, Chris R Kennedy
Neuronal ubiquitin C-terminal hydrolase L1 (UCHL1) is a deubiquitinating enzyme that maintains intracellular ubiquitin pools and promotes axonal transport. Uchl1 deletion in mice leads to progressive axonal degeneration, affecting the dorsal root ganglion that harbours axons emanating to the kidney. Innervation is a crucial regulator of renal hemodynamics, though the contribution of neuronal UCHL1 to this is unclear. Immunofluorescence revealed significant neuronal UCHL1 expression in mouse kidney, including periglomerular axons...
May 8, 2018: Clinical Science (1979-)
https://www.readbyqxmd.com/read/29706566/fgf21-prevents-angiotensin-ii-induced-hypertension-and-vascular-dysfunction-by-activation-of-ace2-angiotensin-1-7-axis-in-mice
#4
Xuebo Pan, Yihui Shao, Fan Wu, Yuan Wang, Rongrong Xiong, Jujia Zheng, Haishan Tian, Baile Wang, Yanfang Wang, Yi Zhang, Zongsheng Han, Aijuan Qu, Haixia Xu, Aihua Lu, Tianxin Yang, Xiaokun Li, Aimin Xu, Jie Du, Zhuofeng Lin
Fibroblast growth factor 21 (FGF21) is a metabolic hormone with pleiotropic effects on glucose and lipid metabolism and insulin sensitivity. However, the role of FGF21 in hypertension remains elusive. Here we show that FGF21 deficiency significantly exacerbates angiotensin II-induced hypertension and vascular dysfunction, whereas such negative effects are reversed by replenishment of FGF21. Mechanistically, FGF21 acts on adipocytes and renal cells to promote induction of angiotensin-converting enzyme 2 (ACE2), which in turn converts angiotensin II to angiotensin-(1-7), then inhibits hypertension and reverses vascular damage...
April 24, 2018: Cell Metabolism
https://www.readbyqxmd.com/read/29697397/pathomorphology-of-the-myocardium-kidney-and-liver-in-spontaneously-hypertensive-rats-treated-with-short-and-long-term-use-ramipril-and-candesartan
#5
A Maruschak, E Shorikov, I Timofiichuk, I Davydenko, K Slobodyan
Choosing a method of treating arterial hypertension remains an urgent problem today. For effective therapy, it is necessary to select hypotensive drugs that not only effectively reduce the pressure, but also contribute to the restoration of the structure of tissues sensitive to oscillations of arterial pressure. The purpose of this study was to conduct a comparative analysis of the effect of angiotensin 2-candesartan receptor antagonist and angiotensin converting factor ramipril on pathomorphological changes in the myocardium, kidney, and liver in SHR lines that received treatment for 7 days (short) and 21 days (prolonged therapy ) The study was conducted on 20 spontaneously hypertensive rats with a mass of 248...
March 2018: Georgian Medical News
https://www.readbyqxmd.com/read/29691064/novel-ace2-fc-chimeric-fusion-provides-long-lasting-hypertension-control-and-organ-protection-in-mouse-models-of-systemic-renin-angiotensin-system-activation
#6
Pan Liu, Jan Wysocki, Tomokazu Souma, Minghao Ye, Veronica Ramirez, Bisheng Zhou, Lisa D Wilsbacher, Susan E Quaggin, Daniel Batlle, Jing Jin
Angiotensin-converting enzyme 2 (ACE2) is a carboxypeptidase that potently degrades angiotensin II to angiotensin 1-7. Previous studies showed that injection of the enzymatic ectodomain of recombinant ACE2 (rACE2) markedly increases circulatory levels of ACE2 activity, and effectively lowered blood pressure in angiotensin II-induced hypertension. However, due to the short plasma half-life of rACE2, its therapeutic potential for chronic use is limited. To circumvent this, we generated a chimeric fusion of rACE2 and the Ig fragment Fc segment to increase its plasma stability...
April 21, 2018: Kidney International
https://www.readbyqxmd.com/read/29679000/valsartan-alleviates-insulin-resistance-in-skeletal-muscle-of-chronic-renal-failure-rats
#7
Yang Wang, Ri-Bao Wei, Yue Yang, Ting-Yu Su, Meng-Jie Huang, Ping Li, Xiang-Mei Chen
BACKGROUND Studies on insulin resistance (IR) in chronic kidney disease (CKD) patients are rare, and its exact mechanism remains unclear. In this study, we explored the molecular mechanism of IR with chronic renal failure (CRF) and interventions to alleviate IR in patients with CRF. MATERIAL AND METHODS In vivo and in vitro models of CRF were established by 5/6 nephrectomy and urea stimulation C2C12 cells, respectively. Based on the CRF model, angiotensin II (Ang II) and valsartan groups were established to observe the effect of drug intervention on IR...
April 21, 2018: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/29665833/intervention-using-vitamin-d-for-elevated-urinary-albumin-in-type-2-diabetes-mellitus-ideal-2-study-study-protocol-for-a-randomised-controlled-trial
#8
Shahrad Taheri, Muhammad Asim, Hassan Al Malki, Omar Fituri, Manikkam Suthanthiran, Phyllis August
BACKGROUND: The prevalence of type 2 diabetes mellitus (T2DM) is increasing worldwide. T2DM is associated with serious macro- and microvascular complications. In particular, diabetic kidney disease (DKD), which begins with excessive urinary albumin excretion, has a significant impact on affected individuals and is costly to healthcare services. Inhibition of the renin-angiotensin-aldosterone system (RAAS) with angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) significantly reduces albuminuria in diabetes, but this effect is not observed in all those treated...
April 17, 2018: Trials
https://www.readbyqxmd.com/read/29655829/renal-effects-and-associated-outcomes-during-angiotensin-neprilysin-inhibition-in-heart-failure
#9
Kevin Damman, Mauro Gori, Brian Claggett, Pardeep S Jhund, Michele Senni, Martin P Lefkowitz, Margaret F Prescott, Victor C Shi, Jean L Rouleau, Karl Swedberg, Michael R Zile, Milton Packer, Akshay S Desai, Scott D Solomon, John J V McMurray
OBJECTIVES: The purpose of this study was to evaluate the renal effects of sacubitril/valsartan in patients with heart failure and reduced ejection fraction. BACKGROUND: Renal function is frequently impaired in patients with heart failure with reduced ejection fraction and may deteriorate further after blockade of the renin-angiotensin system. METHODS: In the PARADIGM-HF (Prospective Comparison of ARNI with ACE inhibition to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial, 8,399 patients with heart failure with reduced ejection fraction were randomized to treatment with sacubitril/valsartan or enalapril...
April 5, 2018: JACC. Heart Failure
https://www.readbyqxmd.com/read/29655688/novel-ras-inhibitor-25-o-methylalisol-f-attenuates-epithelial-to-mesenchymal-transition-and-tubulo-interstitial-fibrosis-by-selectively-inhibiting-tgf-%C3%AE-mediated-smad3-phosphorylation
#10
Hua Chen, Tian Yang, Min-Chang Wang, Dan-Qian Chen, Yang Yang, Ying-Yong Zhao
BACKGROUND: Tubulo-interstitial fibrosis (TIF) is the common pathway in the chronic kidney disease (CKD). Epithelial-to-mesenchymal transition (EMT) is a major contributor to the TIF by the increased myofibroblasts. Renin-angiotensin system (RAS) is critical mediator on EMT in progressive CKD. Angiotensin II (ANG) mediates EMT and causes TIF by stimulating transforming growth factor-β1 (TGF-β1). RAS activation could further activate TGF-β1. Inhibition of the RAS is one of the most powerful therapies for progressive CKD...
March 15, 2018: Phytomedicine: International Journal of Phytotherapy and Phytopharmacology
https://www.readbyqxmd.com/read/29629277/weight-loss-has-an-additive-effect-on-the-proteinuria-reduction-of-angiotensin-ii-receptor-blockers-in-hypertensive-patients-with-chronic-kidney-disease
#11
Shin Young Ahn, Dong Ki Kim, Seung Seok Han, Jung Hwan Park, Sung Joon Shin, Sang Ho Lee, Bum Soon Choi, Chun Soo Lim, Suhnggwon Kim, Ho Jun Chin
Background: Weight reduction is a lifestyle intervention that has been introduced for prevention and management of chronic kidney disease (CKD). We investigate the additive anti-proteinuric effect of weight reduction on the usage of angiotensin II receptor blockers (ARBs) and its potential mechanisms in hypertensive CKD patients. Methods: This study is a subanalysis of data from an open-label, randomized, controlled clinical trial. Among the 235 participants, 227 were assigned to subgroups according to changes in body weight...
March 2018: Kidney Research and Clinical Practice
https://www.readbyqxmd.com/read/29606261/prognosis-and-treatment-of-diabetic-nephropathy-recent-advances-and-perspectives
#12
Peter Rossing, Frederik Persson, Marie Frimodt-Møller
Approximately 20 to 40% of patients with type 1 or type 2 diabetes develop diabetic kidney disease. It is a clinical syndrome characterized by persistent albuminuria (>300mg/24h, or 300mg/g creatinine), a relentless decline in glomerular filtration rate, raised arterial blood pressure and enhanced cardiovascular morbidity and mortality. The natural course of classical diabetic nephropathy is initially microalbuminuria or moderately increased urine albumin excretion (30-300mg/g creatinine). Untreated microalbuminuria may then rise gradually, reaching severely increased albuminuric (macroalbuminuria) over 5 to 15 years...
April 2018: Néphrologie & Thérapeutique
https://www.readbyqxmd.com/read/29593848/saturated-fatty-acids-bound-to-albumin-enhance-osteopontin-expression-and-cleavage-in-renal-proximal-tubular-cells
#13
Alyssa Cobbs, Kristopher Ballou, Xiaoming Chen, Jasmine George, Xueying Zhao
Osteopontin (OPN) is one of the proinflammatory cytokines upregulated in the kidneys of diabetic animals and patients with nephropathy. An increase in urinary albumin and albumin-bound fatty acids (FA) presents a proinflammatory environment to the proximal tubules in proteinuric kidney diseases including diabetic nephropathy. This study was designed to examine if FA overload could stimulate OPN expression and cleavage in renal tubule epithelial cells. OPN gene and protein expression was examined in the kidney of Zucker diabetic (ZD) rats and cultured proximal tubular cells exposed to either bovine serum albumin (BSA) or BSA conjugated with palmitic acid (PA), the most abundant saturated plasma FA...
2018: International Journal of Physiology, Pathophysiology and Pharmacology
https://www.readbyqxmd.com/read/29579289/comparative-efficacy-of-individual-renin-angiotensin-system-inhibitors-on-major-renal-outcomes-in-diabetic-kidney-disease-a-network-meta-analysis
#14
Juyu Cai, Xianxi Huang, Zhongsheng Zheng, Qing Lin, Mian Peng, Daoqian Shen
Background: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are two drug classes with well-documented renal protective effects. However, whether there is any difference among individual drugs remains unknown. In this study, we aimed to compare the efficacy of individual ACEIs/ARBs on major renal outcomes in adults with diabetic kidney disease (DKD). Methods: We conducted a Bayesian-framework network meta-analysis with a random effects model...
March 22, 2018: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/29572286/add-on-antihypertensive-medications-to-angiotensin-aldosterone-system-blockers-in-diabetes-a-comparative-effectiveness-study
#15
Emily B Schroeder, Michel Chonchol, Susan M Shetterly, J David Powers, John L Adams, Julie A Schmittdiel, Gregory A Nichols, Patrick J O'Connor, John F Steiner
BACKGROUND AND OBJECTIVES: In individuals with diabetes, the comparative effectiveness of add-on antihypertensive medications added to an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker on the risk of significant kidney events is unknown. DESIGN, SETTING PARTICIPANTS, & MEASUREMENTS: We used an observational, multicenter cohort of 21,897 individuals with diabetes to compare individuals who added β -blockers, dihydropyridine calcium channel blockers, loop diuretics, or thiazide diuretics to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers...
May 7, 2018: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/29570672/impact-of-the-no-sensitive-guanylyl-cyclase-1-and-2-on-renal-blood-flow-and-systemic-blood-pressure-in-mice
#16
Evanthia Mergia, Manuel Thieme, Henning Hoch, Georgios Daniil, Lydia Hering, Mina Yakoub, Christina Rebecca Scherbaum, Lars Christian Rump, Doris Koesling, Johannes Stegbauer
Nitric oxide (NO) modulates renal blood flow (RBF) and kidney function and is involved in blood pressure (BP) regulation predominantly via stimulation of the NO-sensitive guanylyl cyclase (NO-GC), existing in two isoforms, NO-GC1 and NO-GC2. Here, we used isoform-specific knockout (KO) mice and investigated their contribution to renal hemodynamics under normotensive and angiotensin II-induced hypertensive conditions. Stimulation of the NO-GCs by S -nitrosoglutathione (GSNO) reduced BP in normotensive and hypertensive wildtype (WT) and NO-GC2-KO mice more efficiently than in NO-GC1-KO...
March 23, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29570510/two-pharmacological-epoxyeicosatrienoic-acid-enhancing-therapies-are-effectively-antihypertensive-and-reduce-the-severity-of-ischemic-arrhythmias-in-rats-with-angiotensin-ii-dependent-hypertension
#17
Luděk Červenka, Zuzana Husková, Libor Kopkan, Soňa Kikerlová, Lenka Sedláková, Zdenka Vaňourková, Petra Alánová, František Kolář, Bruce D Hammock, Sung H Hwang, John D Imig, John R Falck, Janusz Sadowski, Elzbieta Kompanowska-Jezierska, Jan Neckář
OBJECTIVE: We examined the effects of treatment with soluble epoxide hydrolase inhibitor (sEHi) and epoxyeicosatrienoic acids (EETs) analogue (EET-A), given alone or combined, on blood pressure (BP) and ischemia/reperfusion myocardial injury in rats with angiotensin II (ANG II)-dependent hypertension. METHODS: Ren-2 transgenic rats (TGR) were used as a model of ANG II-dependent hypertension and Hannover Sprague-Dawley rats served as controls. Rats were treated for 14 days with sEHi or EET-A and BP was measured by radiotelemetry...
March 22, 2018: Journal of Hypertension
https://www.readbyqxmd.com/read/29564978/determinants-of-progression-in-early-autosomal-dominant-polycystic-kidney-disease-is-it-blood-pressure-or-renin-angiotensin-aldosterone-system-blockade
#18
Godela M Brosnahan, Kaleab Z Abebe, Charity G Moore, Kyongtae T Bae, William E Braun, Arlene B Chapman, Michael F Flessner, Peter C Harris, Marie C Hogan, Ronald D Perrone, Frederic F Rahbari-Oskoui, Theodore I Steinman, Vicente E Torres, The Halt Pkd Investigators
BACKGROUND: The HALT PKD trial in early autosomal dominant polycystic kidney disease (ADPKD) showed that intensive control of systolic blood pressure to 95-110 mmHg was associated with a 14% slower rate of kidney volume growth compared to standard control. It is unclear whether this result was due to greater blockade of the renin-angiotensin-aldosterone system (RAAS) by allowing the use of higher drug doses in the low blood pressure arm, or due to the lower blood pressure per se. METHODS: In this secondary analysis of HALT PKD Study A, we categorized participants into high and low dose groups based on the median daily equivalent dose of RAAS blocking drugs used after the initial dose titration period...
March 21, 2018: Current Hypertension Reviews
https://www.readbyqxmd.com/read/29562806/a-randomized-intervention-study-to-evaluate-the-effect-of-calcitriol-therapy-on-the-renin-angiotensin-system-in-diabetes
#19
Sarah Zaheer, Kiara Taquechel, Jenifer M Brown, Gail K Adler, Jonathan S Williams, Anand Vaidya
BACKGROUND: Prior studies suggest that vitamin D therapy may decrease cardiovascular disease risk in type 2 diabetes (T2DM) by lowering renin-angiotensin system (RAS) activity. However, randomized human intervention studies to evaluate the effect of vitamin D receptor (VDR) agonists on RAS activity are lacking. OBJECTIVE: The objective of this article is to investigate the effect of direct VDR activation with calcitriol on circulating RAS activity and vascular hemodynamics in T2DM...
January 2018: Journal of the Renin-angiotensin-aldosterone System: JRAAS
https://www.readbyqxmd.com/read/29554877/factors-associated-with-residual-urine-volume-preservation-in-patients-undergoing-hemodialysis-for-end-stage-kidney-disease-in-kinshasa
#20
Vieux Momeme Mokoli, Ernest Kiswaya Sumaili, François Bompeka Lepira, Fiston Ikwa Ndol Mbutiwi, Jean Robert Rissassy Makulo, Justine Busanga Bukabau, Patrick Parmba Izeidi, Jeannine Losa Luse, Stéphane Kalambay Mukendi, Désiré Kulimba Mashinda, Nazaire Mangani Nseka
BACKGROUND: Decreased residual urine volume (RUV) is associated with higher mortality in hemodialysis (HD). However, few studies have examined RUV in patients on HD in Sub-Saharan Africa. The aim of this study was to identify predictors of RUV among incident hemodialysis patients in Kinshasa. METHODS: This historical cohort study enrolled 250 patients with ESRD undergoing hemodialysis between January 2007 and July 2013 in two hemodialysis centers in Kinshasa. RUV were collected over 24 h at the initiation of HD and 6 and 12 months later during the interdialytic period...
March 20, 2018: BMC Nephrology
keyword
keyword
114527
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"